Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Thomas Wolfel"'
Autor:
Erika Dittmar, Thomas Wolfel, Lourdes Menendez, Jessilyn Pozo, Maygret Ramirez, Starlie C. Belnap, Felipe De Los Rios La Rosa
Publikováno v:
Annals of Pharmacotherapy. :106002802211494
Background: Recent evidence suggests tenecteplase at an intravenous dose of 0.25 mg/kg is as safe and efficacious as intravenous alteplase standard dose and demonstrates a more favorable pharmacokinetic profile for treatment of acute ischemic stroke.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fdc5e4e9f3e3100815e130e1c5dbf07
https://doi.org/10.1177/10600280221149409
https://doi.org/10.1177/10600280221149409
Autor:
Michael Volkmar, Elham Fakhr, Stefan Zens, Alice Bury, Rienk Offringa, Jessica Gordon, Enes Huduti, Thomas Wölfel, Catherine Wölfel
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Here, we describe the identification of two T-cell receptors (TRs) containing TRDV genes in their TRA chains, the first one in human and the second one in mouse. First, using 5’RACE on a mixed lymphocyte-tumor cell culture (MLTC), we identified TRD
Externí odkaz:
https://doaj.org/article/a94935e9201446238650f1a5f250b8d8
Autor:
Korbinian N. Kropp, Martina Fatho, Enes Huduti, Marilena Faust, Silke Lübcke, Volker Lennerz, Annette Paschen, Matthias Theobald, Thomas Wölfel, Catherine Wölfel
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntorductionChondroitin sulfate proteoglycan 4 (CSPG4), also known as high molecular weight-melanoma associated antigen, is expressed in melanoma but also other tumor entities and constitutes an attractive target for immunotherapeutic approaches. Whi
Externí odkaz:
https://doaj.org/article/876d109a9f104f8e9183472e9034a50a
Publikováno v:
Cancer Therapeutic Targets ISBN: 9781461466130
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b56803a9b4bec9bb825d71c3851ffa5e
https://doi.org/10.1007/978-1-4614-6613-0_102-4
https://doi.org/10.1007/978-1-4614-6613-0_102-4
Autor:
Maximilian Higer, Denis Cana, Juergen Podlech, Simin Schadmand-Fischer, Andreas Schwarting, Daniel Teschner, Matthias Theobald, Thomas Wölfel, Georg Hess
Publikováno v:
Journal of Medical Case Reports, Vol 14, Iss 1, Pp 1-6 (2020)
Abstract Background Rituximab is a well-established component of treatment regimens for B-cell non-Hodgkin lymphoma. Rituximab binds the CD20 antigen on the surface of B lymphocytes, causing an enhanced clearance of malignant and benign B cells. Thus
Externí odkaz:
https://doaj.org/article/46dfc735ee124afe8cbeaa1d46c98087
Autor:
Korbinian N Kropp, Tim J Schäufele, Martina Fatho, Michael Volkmar, Roland Conradi, Matthias Theobald, Thomas Wölfel, Catherine Wölfel
Publikováno v:
PLoS ONE, Vol 15, Iss 9, p e0238875 (2020)
To facilitate preclinical testing of T-cell receptors (TCRs) derived from tumor-reactive T-cell clones it is necessary to develop convenient and rapid cloning strategies for the generation of TCR expression constructs. Herein, we describe a pDONR™2
Externí odkaz:
https://doaj.org/article/945f4e5a0b6a43829474d7d811db6425
Autor:
Vijay Kumar Singh, Sebastian Werner, Simone Schwalm, Volker Lennerz, Stephanie Ruf, Serena Stadler, Holger Hackstein, Alfred Reiter, Thomas Wölfel, Christine Damm-Welk, Wilhelm Woessmann
Publikováno v:
OncoImmunology, Vol 8, Iss 9 (2019)
The oncoantigen nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces cellular and humoral immune responses in patients with NPM-ALK-positive anaplastic large cell lymphoma (ALCL). We characterize the NPM-ALK-specific T-cell responses in a cohor
Externí odkaz:
https://doaj.org/article/1f013a88322d4968a640b20c954c6ba3
Autor:
Natalia Pieper, Anne Zaremba, Sonia Leonardelli, Franziska Noelle Harbers, Marion Schwamborn, Silke Lübcke, Barbara Schrörs, Jolanthe Baingo, Alexander Schramm, Sebastian Haferkamp, Ulrike Seifert, Antje Sucker, Volker Lennerz, Thomas Wölfel, Dirk Schadendorf, Bastian Schilling, Annette Paschen, Fang Zhao
Publikováno v:
OncoImmunology, Vol 7, Iss 8 (2018)
The profound but frequently transient clinical responses to BRAFV600 inhibitor (BRAFi) treatment in melanoma emphasize the need for combinatorial therapies. Multiple clinical trials combining BRAFi and immunotherapy are under way to further enhance t
Externí odkaz:
https://doaj.org/article/ba763546e68d4a68931ae0d1bfff33bf